Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.38 |
| ▸ | IGF1R | P08069 | 1/20 | 0.38 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.38 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11237396 | 0.82 | L3MBTL1 (1.00) | L3MBTL1KMT2AMEN1GAASMN1; SMN2 | |
| SCHEMBL11255920 | 0.82 | L3MBTL1 (0.80) | L3MBTL1KMT2AMEN1GAASMN1; SMN2 | |
| SCHEMBL11240303 | 0.82 | L3MBTL1 (0.74) | L3MBTL1KMT2AMEN1GAASMN1; SMN2 | |
| SCHEMBL11248107 | 0.78 | L3MBTL1 (0.61) | L3MBTL1KMT2AMEN1GAASMN1; SMN2 | |
| SCHEMBL11268300 | 0.77 | L3MBTL1 (0.72) | L3MBTL1KMT2AMEN1GAASMN1; SMN2 | |
| SCHEMBL11253505 | 0.77 | L3MBTL1 (0.60) | L3MBTL1KMT2AMEN1GAASMN1; SMN2 | |
| SCHEMBL11249668 | 0.77 | L3MBTL1 (0.67) | L3MBTL1KMT2AMEN1GAASMN1; SMN2 | |
| SCHEMBL8888929 | 0.77 | L3MBTL1 (0.59) | L3MBTL1KMT2AMEN1GAASMN1; SMN2 | |
| SCHEMBL16703917 | 0.76 | L3MBTL1 (0.59) | L3MBTL1KMT2AMEN1GAASMN1; SMN2 | |
| SCHEMBL11246293 | 0.76 | L3MBTL1 (0.69) | L3MBTL1KMT2AMEN1GAASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170267648-A1 | SUBSTITUTED URACILS AS CHYMASE INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-09-21 | — | — | US | disclosed |
| US-9695131-B2 | Substituted uracils as chymase inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-07-04 | — | — | US | disclosed |
| EP-3066096-A1 | SUBSTITUTED URACILS AS CHYMASE INHIBITORS | Bayer Pharma Aktiengesellschaft (DE) | 2016-09-14 | — | — | EP | disclosed |
| US-20160244415-A1 | SUBSTITUTED URACILS AS CHYMASE INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-08-25 | — | — | US | disclosed |
| WO-2015067651-A1 | SUBSTITUTED URACILS AS CHYMASE INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-05-14 | — | — | WO | disclosed |
| US-4338318-A | FUNGICIDE OR BACERICIDE TO TREAT PLANT DISEASES WITH A PHENYL URACIL | ZOECON CORPORATION (US) | 1982-07-06 | — | — | US | disclosed |
| US-4297297-A | α-Cyano-β-(substituted-anilino)-N-ethoxycarbonylacrylamide intermediates | ZOECON CORP. (US) | 1981-10-27 | — | — | US | disclosed |
| US-4266056-A | FUNGICIDES, BACTERICIDES | ZOECON CORPORATION (US) | 1981-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170267648-A1 | SUBSTITUTED URACILS AS CHYMASE INHIBITORS | CMA1, UNG, TYMP | L3MBTL1 785/4885KMT2A 3644/4885MEN1 2730/4885 |
| US-20160244415-A1 | SUBSTITUTED URACILS AS CHYMASE INHIBITORS | UNG, CMA1, TYMP | L3MBTL1 2468/4885KMT2A 3293/4885MEN1 1807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.